Print Share

Haemophilus Influenzae Type b (Hib) Vaccine

Institution:

School of Medicine and Dentistry at the University of Rochester Medical Center

Researchers:

David H. Smith, M.D. (deceased), Porter W. Anderson, Ph.D., University of Rochester School of Medicine and Dentistry

Impact:

Before the Hib vaccine was available, Hib disease was the leading cause of bacterial meningitis among children under 5 years old in the U.S. Hib disease can also cause pneumonia; severe swelling in the throat; infections of the blood, joints, bones, and covering of the heart; and death. Since the vaccine was introduced, bacterial meningitis has been reduced by about 98 percent.

Timeline:

The Hib vaccine was approved for use in the U.S. in 1990.  

Topics

AgingBasic ScienceCancerCardiovascularClinical ResearchDiagnosticsDrug DevelopmentFeaturedGeneticsImmune SystemInfectious DiseaseMedical DeviceMental HealthNeurodegenerativeNobel PrizePediatricsPublic HealthRespiratorySurgical AdvancementTechnologyTreatment AdvancesVaccines

Schools

Albany Medical CollegeAlbert Einstein College of MedicineCity University of New York School of MedicineColumbia University College Of Physicians and SurgeonsHofstra Northwell School of Medicine at Hofstra UniversityIcahn School of Medicine at Mount SinaiJacobs School of Medicine and Biomedical Sciences, the University at BuffaloNew York Institute of Technology College of Osteopathic MedicineNew York Medical CollegeNew York University School of MedicineSchool of Medicine and Dentistry at the University of Rochester Medical CenterStony Brook University School of MedicineSUNY Downstate Medical CenterSUNY Upstate Medical UniversityTouro College of Osteopathic MedicineWeill Cornell MedicineWeill Cornell Medicine, NewYork-Presbyterian